



October 30, 2003

Dr. Jim Dailey
6807 Crossmoor Lane
Louisville, KY 40222-6535

Dear Dr. Dailey:

AstraZeneca would like to cordially invite you to participate in the SEROQUEL (quetiapine fumarate) Consultant Meeting that will be held December 16, 2003 at the AstraZeneca US Business Center, 1800 Concord Pike, Brandywine Building, Wilmington, Delaware. The day will commence with lunch at noon followed by afternoon meetings to end by 5:00 pm.

The purpose of the SEROQUEL Consultant Program is to discuss ways that AstraZeneca can better partner with our Consumer Groups at the National, Regional and local levels. For your participation in this consultant program, you will receive an honorarium of \$500.00, round trip coach class airfare with ground transportation to and from the Philadelphia airport (where applicable). Related travel expenses will also be reimbursed via a \$100 stipend.

To confirm your attendance to the SEROQUEL Consultant Program, please complete the attached form and fax it to Leave It to LaFever, Ltd. at 412-262-7895 by November 20, 2003. A confirmation letter with specific meeting details will follow.

On behalf of AstraZeneca, we would like to thank you for considering this opportunity to participate in the SEROQUEL Consultant Program. If you have any questions with regard to this program, please feel free to contact Lynette LaFever at 412-262-7960. We look forward to seeing you and to working with you in the future.

Please note AstraZeneca fully supports and abides by the PhRMA Code on Interactions with Healthcare Professionals and as a result will not pay for the attendance of spouses or guests at this program. If you wish to have your spouse or guest with you, you will be responsible for those expenses.

Sincerely,

Jodie Ross
Customer Alignment Manager
CNS Detroit Region
AstraZeneca, L.P.

Seroquel is a registered trademark of the AstraZeneca group of companies.
© 2002 AstraZeneca Pharmaceuticals LP



PROFESSIONAL SERVICES AGREEMENT

[Individual]

This Professional Services Agreement (this "Agreement") is made effective as of December 16, 2003, (the "Effective Date"), by and between *AstraZeneca Pharmaceuticals LP*, a Delaware limited partnership with offices at *1800 Concord Pike, Wilmington, Delaware 19803* ("AstraZeneca") and **JIM DAILEY**, individual with *her/his* principal place of business at *6807 Crossmoor Lane, Louisville, KY 40222* ("Professional").

Background: AstraZeneca wants to use the services of the Professional in order to obtain the benefit of the experience and ability of the Professional. The Professional wants to render such services to AstraZeneca and will devote *his/her* best efforts to the services that are to be provided to AstraZeneca.

1. **Services.** AstraZeneca retains the Professional to provide the services set forth on Attachment "A" (the "Services"). Professional shall use *his/her* best efforts in the performance of the Services and shall perform such Services diligently and conscientiously with the highest professional standards and in compliance with all applicable laws, regulations and AstraZeneca policies. Professional shall not use subcontractors for the purpose of performing the Services without the prior written approval of AstraZeneca.
2. **Compensation.** In return for the Services performed under this Agreement, AstraZeneca shall pay to the Professional the fee set forth in Attachment "B." However, with the exception of a reasonable fee (not to exceed 25% of the value of the aggregate Services to be provided under the Agreement) to be paid by AstraZeneca on the Effective Date, AstraZeneca shall at no time pay fees for Services not performed. To the extent the terms set forth in this Section differ from those set forth in Attachment B, this Section shall control.
3. **Expenses.** The Professional shall furnish, at Professional's own expense, any and all materials, equipment, services or supplies necessary or useful to successfully completing the Services. AstraZeneca will reimburse the Professional for authorized and reasonable expenses the Professional incurs in performing the Services, provided that the Professional provides AstraZeneca with a reasonable accounting, together with receipts, for such expenses. The Professional shall not incur any expenses that exceed one thousand dollars (\$1,000.00) for any one item or five thousand dollars (\$5,000.00) in the aggregate in any month without prior written consent from AstraZeneca. At no time shall AstraZeneca reimburse the Professional for expenses related to (a) secretarial or word processing services; (b) staff services; (c) computer time; (d) express delivery services; (e) facsimile charges; (f) photocopying in excess of ten cents per page; or (g) meals (other than meals incurred while traveling).
4. **Method of Payment.** The Professional shall deliver to AstraZeneca, within fifteen days after the end of each calendar month, an invoice for fees and authorized expenses. The invoice shall contain a written progress report detailing the work performed by Professional in connection with the Services and a

reasonable accounting of all reimbursable expenses incurred during such month and supporting documentation for all reimbursable expenses. Within sixty (60) days after the receipt by AstraZeneca of a satisfactory invoice as defined herein, AstraZeneca shall issue a check to the Professional for the applicable amount. AstraZeneca shall have no obligation to reimburse Professional for authorized expenses that are not invoiced within ninety (90) days after the date the Professional incurred such expense. The Professional acknowledges and agrees that the fees and expenses set forth in Sections 2 and 3 hereof represent AstraZeneca's full and complete obligation for the Services to be rendered, and expenses incurred, by or on behalf of the Professional under this Agreement. To the extent the terms set forth in this Section differ from those set forth in Attachment B, this Section shall control.

5. **Independent Contractor.**

(a) Professional agrees that Professional is acting as an independent contractor in performing the Services and for all other purposes under this Agreement and that the relationship between the Professional and AstraZeneca shall not constitute a partnership, joint venture or agency. Professional is not an employee, agent or legal representative of AstraZeneca and has no authority to represent AstraZeneca or to enter into any contracts or assume any liabilities on behalf of AstraZeneca. PROFESSIONAL AGREES THAT NEITHER THIS AGREEMENT NOR THE SERVICES PERFORMED HEREUNDER SHALL ENTITLE PROFESSIONAL TO PARTICIPATE IN OR ACCRUE OR RECEIVE BENEFITS UNDER ANY PENSION PLAN, DEFERRED CONTRIBUTION PLAN, HEALTH PLAN, LIFE INSURANCE PLAN, OR DISABILITY PLAN, ANY OTHER EMPLOYEE BENEFIT PLAN (AS DEFINED BY THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974), OR ANY ARRANGEMENT, PROGRAM, OR POLICY MAINTAINED BY ASTRAZENECA THAT PROVIDES EMPLOYEE BENEFITS. IN ADDITION, IN THE EVENT PROFESSIONAL IS RECLASSIFIED BY ANY COURT OR AGENCY TO BE AN EMPLOYEE OF ASTRAZENECA, PROFESSIONAL HEREBY EXPRESSLY WAIVES ALL RIGHTS TO PARTICIPATE IN THE PLANS AND ARRANGEMENTS REFERENCED ABOVE FOR THE TERM OF THIS AGREEMENT.

(b) Professional shall be solely and unconditionally responsible for paying any and all city, state and federal taxes and assessments, including, without limitation, all income, social security withholding and self-employment taxes, relating to any income or other consideration that Professional derives from this Agreement.

6. **Ownership of Work Product.**

(a) All materials, documents, data, software, information and inventions supplied to Professional by or on behalf of AstraZeneca shall be and remain the sole and exclusive property of AstraZeneca. All such property shall be delivered to AstraZeneca by Professional immediately upon demand.

(b) Professional shall make full disclosure to AstraZeneca of all inventions, discoveries, know-how, software, work, reports, presentations, writings, ideas, designs and other information in any form that are created, developed, written, conceived or made by Professional (whether solely or jointly with others) as a result of or in connection with the Services and any

patent, trade secret or other intellectual property rights with respect thereto (collectively, “**Work Product**”). Professional agrees that all Work Product that is copyrightable subject matter shall be considered “work made for hire” within the meaning of the copyright laws of the United States and that AstraZeneca is and shall be the sole author of the Work Product and the sole owner of all rights therein in perpetuity. With respect to any Work Product that is not “work made for hire,” Professional hereby irrevocably assigns without additional consideration, to AstraZeneca in perpetuity all of Professional’s right, title and interest worldwide in and to such Work Product. At AstraZeneca’s request and expense, Professional shall execute all documents and take all actions that AstraZeneca reasonably deems necessary to perfect AstraZeneca’s ownership of the Work Product.

(c) Professional represents, warrants and covenants that Professional has the right to make the assignments to AstraZeneca set forth in this Section 6 and that ownership and use of the Work Product by or on behalf of AstraZeneca will not constitute an infringement of any third-party patent, trademark, copyright, trade secret or other proprietary right (except in those instances where Professional has notified AstraZeneca thereof in writing at the time of such assignments or grants).

7. **Confidential Information.** Professional acknowledges and agrees that Professional will have access to, or become acquainted with, Confidential Information of AstraZeneca in the performance of the Services. For purposes of this Agreement, “Confidential Information” shall mean all confidential, proprietary, or trade secret information, property, or material of AstraZeneca and any derivatives, portions, or copies thereof, including, without limitation, information resulting from or in any way related to (i) the Services; (ii) the business practices, plans, or relationships of AstraZeneca; and (iii) any other information or material that AstraZeneca designates as Confidential Information. Professional shall keep all Confidential Information in strict confidence and shall not, at any time during or for ten (10) years after the expiration or earlier termination of this Agreement, without AstraZeneca’s prior written consent, disclose, publish, disseminate or otherwise make available, directly or indirectly, any item of Confidential Information to anyone. Professional shall use the Confidential Information only in connection with the performance of the Services hereunder and for no other purpose.

8. **Equitable Relief.** Professional recognizes that any threatened breach or breach of Sections 6 or 7 will cause irreparable harm to AstraZeneca that is inadequately compensable in damages and that, in addition to other remedies that may be available at law or equity, AstraZeneca is entitled to injunctive relief for such a threatened or actual breach of Section 6 or 7.

9. **Term.** The Term of this Agreement shall be no longer than one (1) year unless terminated earlier as provided by this Agreement. Either party may terminate this Agreement on thirty (30) days written notice. Notwithstanding the foregoing provision, AstraZeneca may immediately terminate this Agreement if the Professional breaches or threatens to breach any provision of this Agreement. Upon expiration of the Agreement or termination, the Professional shall immediately deliver to AstraZeneca all Work Product and property of AstraZeneca. The

Agreement may be renewed for additional one-year terms (not to exceed two additional one-year terms) by the mutual written agreement of the parties.

10. **Indemnification.** Professional shall defend, indemnify, and hold harmless AstraZeneca, its Affiliates and their respective officers, directors, partners, shareholders, employees, and agents from and against any and all liabilities, claims, demands, causes of action, damages, losses and expenses, including, without limitation, attorneys' fees, (collectively, "Losses") arising out of or in connection with (a) any negligence or intentional misconduct of Professional in the performance of the Services, (b) any breach by Professional of its obligations under this Agreement, and (c) any Losses arising out of or related to any of the matters identified in Section 5, or as a result of any determination or allegation that Professional is an Employee of AstraZeneca. Affiliates shall mean any corporation or other business entity that controls, is controlled by or under common control with AstraZeneca PLC.

11. **Insurance.** Professional shall maintain at Professional's own expense full insurance coverage for Professional and Professional's Employees, including, without limitation, (a) errors and omissions insurance covering services of the type performed by Professional under this Agreement, with minimum limits of five million dollars (\$5,000,000) per event and five million dollars (\$5,000,000) general aggregate and including coverage for contractual liabilities; (b) commercial general liability insurance covering claims for damages because of bodily injury (including death), personal injury, advertising injury and property damage arising out of acts or omissions of Professional's Employees with minimum limits of one million dollars (\$1,000,000) per occurrence and two million dollars (\$2,000,000) in the aggregate and including coverage for contractual liabilities; and (c) commercial automobile liability insurance covering owned, hired and non-owned vehicles. Professional shall also maintain workers' compensation insurance as required by all applicable laws. Each of the above policies of insurance (1) shall cover claims arising out of the performance of this Agreement that are made within a period of not less than three (3) years after its expiration or earlier termination, and (2) shall be primary to any liability insurance carried by AstraZeneca, which insurance shall be excess and non-contributory for claims and losses arising out of the performance of this Agreement. The policies identified in Sections 11(b) and (c) shall be specifically endorsed to list AstraZeneca as an additional insured. Professional shall provide AstraZeneca with a certificate from the insurer(s), evidencing the insurance coverage required under this Section and agreeing to notify AstraZeneca at least thirty (30) days in advance of any cancellation of such insurance coverage. Maintenance of such insurance coverage shall not relieve Professional of any responsibility under this Agreement for damages in excess of insurance limits or otherwise.

12. **Representations, Warranties and Covenants of Professional.**

(a) Professional represents and warrants that Professional is free to enter into this Agreement and perform the Services. Professional further represents, warrants and covenants that Professional's retention by AstraZeneca and Professional's performance of the Services do not, and will not, breach any agreement that obligates Professional to keep in confidence any trade secrets or confidential information of Professional or of any other party or to refrain from competing, directly or indirectly, with the business of any other party.

(b) Professional represents, warrants and covenants that: (i) Professional is, and at all times during the Term of this Agreement will be, qualified by training and experience with appropriate expertise to perform the Services, (ii) Professional has, and at all times during the Term of this Agreement will have, appropriate licenses, approvals and certifications necessary to perform safely, adequately and lawfully its obligations under this Agreement, and (iii) neither Professional nor any of Professional's family holds, or at any time during the Term of this Agreement will hold, without the express written prior approval of AstraZeneca, any financial interest in AstraZeneca or its Affiliates.

(c) Professional represents and warrants that entering into this Agreement and performing the Services hereunder does not and will not cause Professional to be in non-compliance with any policy or procedure of any institution or entity by which he or she is employed. Professional further warrants that the institution has no financial, proprietary or other interest in (i) the Services that Professional is conducting, (ii) the fees that are being paid to the Professional for the performance of the Services, or (iii) the results of the Services.

13. **Regulatory Inspections.** If any governmental or regulatory authority (a) contacts Professional with respect to the Services, (b) conducts, or gives notice of its intent to conduct, an inspection of Professional or (c) takes, or gives notice of its intent to take, any other regulatory action alleging improper or inadequate practices with respect to any activity of Professional, whether or not in connection with the Services, Professional shall notify AstraZeneca within three (3) business days after such contact or notice, or sooner if necessary to permit AstraZeneca to be present at, or otherwise participate in, any such inspection or regulatory action with respect to the Services, and shall supply AstraZeneca with all information pertinent thereto. AstraZeneca shall have the right to be present at and to participate in any such inspection or regulatory action with respect to the Services. Professional shall provide AstraZeneca with copies of all documentation issued by any governmental or regulatory authority in connection therewith and any proposed response thereto. No such response shall include any false or misleading information with respect to the Services or AstraZeneca.

14. **Debarment.** Professional represents, warrants and covenants that Professional is not debarred or subject to debarment under 21 U.S.C. § 335(a) or otherwise disqualified or suspended from performing the Services or otherwise subject to any restrictions or sanctions by the FDA or any other governmental or regulatory authority or professional body with respect to the performance of the Services (a "**Debarred Person**"). Professional shall immediately notify AstraZeneca in writing if Professional is or becomes a Debarred Person or if any action, suit, claim, investigation, or other legal or administrative proceeding is pending or, to the best of

Professional's knowledge, threatened, that would make any person performing services hereunder a Debarred Person or would preclude Professional from performing the Services.

15. **Assignment.** Neither party shall assign this Agreement without the prior written consent of the other party, which consent shall not be unreasonably withheld; provided, however, that AstraZeneca shall have the right to assign or otherwise transfer this Agreement to its Affiliates or to any successor in interest.

16. **Amendment; Waiver.** This Agreement may be amended only by a written instrument signed by the parties hereto. Each party shall have the right to enforce the provisions of this Agreement in strict accordance with its terms. The failure of either party at any time to enforce its rights hereunder strictly in accordance with the same shall not be construed as having created a custom contrary to the specific provisions hereof or as having in any way modified or waived same.

17. **Governing Law.** This Agreement and the rights and obligations of the parties hereunder shall be governed by and construed under the laws of the State of Delaware without reference to its principles of choice of law. All disputes pertaining to this Agreement shall be decided by a state or federal court located in Wilmington, Delaware, and Professional hereby consents to personal jurisdiction in such courts.

18. **Notices.** Any notice that is required or permitted hereunder shall be deemed given only if delivered personally or sent by telecopy (with transmission confirmed) or by registered or certified mail, return receipt requested and postage prepaid, or by a nationally recognized overnight delivery service, addressed to the parties at their respective addresses first set forth above or to such other addresses at which notice of change shall have been given.

19. **Entire Agreement.** This Agreement, including Attachment A and Attachment B hereto, sets forth and constitutes the entire agreement and understanding between the parties with respect to the subject matter hereof and all prior agreements, understanding, promises and representations, whether written or oral, with respect thereto are superseded hereby.

20. **Severability.** The provisions of this Agreement shall be several. Invalidity or unenforceability of one provision shall not affect any other provision of this Agreement.

21. **Survival.** The respective rights and obligations of the parties set forth in this Agreement shall indefinitely survive the expiration or termination of this Agreement to the extent necessary to the intended preservation of such rights and obligations.

22. **Headings.** The headings in this Agreement are for convenience only and do not in any way limit or amplify their terms in this Agreement.


23. **Use of Name.** Professional shall not mention or otherwise use the name of AstraZeneca (or any abbreviation or adaptation thereof) in any publication, press release, promotional material or other form of publicity without the prior written approval of AstraZeneca in each instance.

24. **Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall together be deemed to constitute one agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.

PROFESSIONAL

ASTRAZENECA PHARMACEUTICALS LP

By: 

By: 

Name: Jim Dailey

Name: Jeff Mollison

Title: State Advocacy Director
NAMI Kentucky

Title: Regional Sales Director

Attachment A

Services

Services to be provided:

The Professional shall attend and fully participate in a speaker development program (the "Program") to be held at the AstraZeneca US Business Center in Wilmington, Delaware on December 16th, 2003. The Program is being given, and the Professional's participation is required, in order to train the Professional as a speaker for AstraZeneca in accordance with the terms of a Speaker Letter Agreement between the Professional and AstraZeneca. The parties contemplate that the Professional will conduct periodic speaking events for AstraZeneca as more fully described in the Speaker Letter Agreement.

Attachment B

Payment Schedule

AstraZeneca will pay the Professional \$500.00 for Professional's attendance at and participation in the Program. The Professional must attend and fully participate in all aspects of the Program in order to receive any compensation.

AstraZeneca will provide a \$100.00 stipend for travel expenses.

412-262-7969
Sign contract
w/9 Reane # to Caffer, LTD
113 Camelot Circle
Coraopolis PA 15108
Sue or Lynette
12/22/03

Jim Dailey

AstraZeneca 

FAX REGISTRATION FORM

SEROQUEL (quetiapine fumarate) Consultant Meeting
AstraZeneca US Business Center in Wilmington, Delaware
December 16, 2003

I accept this invitation to participate in the AstraZeneca 2003 Seroquel Consultant Meeting
 I am unable to accept this invitation, but would like to be considered for future workshops

Please print:

Name: JIM DAILEY, M.D., D.O., other (please circle)

Social Security Number/Tax ID Number 406-60-1428

Do you have any dietary restrictions? Please specify No

TRANSPORTATION NEEDS:

Will you be driving? Circle one: Yes No

Will you be flying? Circle one: Yes No

If you are flying please contact:

Sandy Berardis at Centre for Travel

Toll Free: 1-800-255-2140 Ext. 121

(Identify yourself as AstraZeneca December 16th Program.)

Preferred mailing address: (No P.O. addresses please)

6807 CROSSMOOR LANE

LOUISVILLE, KY 40222

Home Phone: 502-425-9585

Business Phone: 502-245-5284

Office Fax: 502-245-6390

E-Mail address: JPD737@AOL.COM

(optional)

PLEASE FAX THIS FORM WITH THE "CONSULTANT FORM"

NO LATER THAN November 20, 2003 to:

Leave It To LaFever, Ltd.

Fax Response to 412-262-7895

Any questions, call toll-free 1-866-523-3837



**2003 SEROQUEL(quetiapine fumarate)
Consultant Meeting**

**AstraZeneca US Business Center
Wilmington, Delaware
December 16, 2003**

CONSULTANT FORM

Please fill out this form and return to Leave It To LaFever, Ltd., via fax at (412) 262-7895. (Please Print)

As a consultant, you will be asked to sign a consultant contract and to attend the meeting in its entirety on Tuesday, Dec.16, 2003. AstraZeneca reserves the right to confirm participation on a first-come, first-serve basis. Should you decide to register for the meeting as a consultant you will receive:

- *Round-trip coach class airfare, as approved by AstraZeneca*
- *Ground Transportation to and from the hotel*
- *All meals during the meeting*
- *\$500 compensation for services*
- *A travel stipend of \$100.00 for incidental expenses (e.g. parking, mileage, cab fare)*
- *AstraZeneca fully supports and abides by the PhRMA Code on Interactions with Healthcare Professionals and as a result will not pay for incidental expenses or expenses of spouses or guests, including their travel, hotel room, or meals. If your spouse or guest is traveling with you and you wish to have them included in any activities or meals, you will be responsible for those expenses.*

If you agree with the above conditions, please sign below and complete the attached registration form.

Signature  Print Name JAMES P. DAILEY

Please fax with "Registration Form" to 412-262-7895



12/16/03

December 4, 2003

Jim Dailey
6807 Crossmoor Lane
Louisville, KY 40222

Dear Mr. Dailey:

AstraZeneca would like to confirm your attendance at the SEROQUEL (quetiapine fumarate) Consultant Meeting at the AstraZeneca US Business Center, 1800 Concord Pike, Brandywine Building, Wilmington, Delaware on Tuesday, December 16, 2003.

Lodging: N/A

Contact Cell #: Beverly Susman – 513-260-4651

Meeting Schedule: Please arrive at the US Business Center, 1800 Concord Pike, Wilmington, Delaware prior to 11:30 am for lunch with AstraZeneca representatives, Bev Susman and Bryan Clemons.

Air: See Attached

Ground Transportation: Eagle Limousine – Telephone #800-669-5460. AstraZeneca has prepaid for this transportation, including gratuity to the driver. Please see attached ground transportation information.

Dress Code: ~~Business Casual~~ ^{DRESS} for meeting.

Honorarium: There will be a \$500 honorarium, which will be mailed to you **approximately 6 weeks after the program.**

Travel Stipend: A check for \$100.00 will be mailed to you with your honorarium for related travel expenses.

AstraZeneca fully supports and abides by the PhRMA Code of Interactions with Healthcare Professionals and as a result will not pay for incidental expenses or expenses of spouses or guests, including their travel, hotel room, or meals. If your spouse or guest is traveling with you and you wish to have them included in any activities or meals, you will be responsible for those expenses.

**Please notify our Conference Planning Company,
Leave It To LaFever, Ltd.
Toll free at 1-866-523-3837
of any changes or cancellations.**

Eagle Limousine
Reservation Confirmation

PU Date: 12/16/2003 PU Time: 09:01 # of Pass: 1 Chauff.:
Res#: 23326 Start Time: 09:01 Veh Type: SEDAN Vehicle#:

Passenger: Dailey, Jim Pickup Ph: 800-428-4322
Caller: Tina Caller#: 412-262-7960
Account: ONETIME - One Time Pass Paid By: Credit Card - AX


Pickup Address: DropOff Point: AstraZeneca - USBC Vis
Philadelphia International Air 1800 Concord Pk
US
2960M ETA: 09:01

Talleyville DE
Enter off Rte 141. Register at desk
if picking up.

Insurance Surcharge	3.84	Flat Rate	-----	\$64.00
		Wait Time	-----	\$0.00
		UDF Chg. Total	-----	\$3.84
		Gratuity	-----	\$9.60
		Sub Total	-----	\$13.44
		Amount Due	-----	\$77.44

Liability Agreement: Sedan Cancellation Policy: A cancellation fee equal to the total trip cost will be charged for any cancellation that is made less than two hours before the scheduled pick up time in the Wilmington/Philadelphia metro areas. All out of state pick-ups, require four hours notice. Eagle Limousine, Inc. is not responsible for passenger flights, which are missed, cancelled, diverted and delayed or any incident that results in failure to comply with required cancellation policy. In these instances Eagle Limousine will exact our best efforts to fulfill our clients needs, subject to wait time fees or late cancellations and re-bookings, without detriment to other reserved clients.

No Show Policy: A fee of equal the trip cost plus applicable waiting time, tolls, and parking will be charged when the passenger fails to show at the designated location for which a reservation was made.



AstraZeneca Pharmaceuticals
Fax Cover Sheet
502-897-5066

To: Jim Dailey

From: **Bryan Clemons**
502-386-3383 cell

Re: _____

Comments:

Jim,
HERE is the CENTRAL STATE DATA AND
THE AGENDA FOR the MEETING AND ATTENDEES.
LET ME KNOW if you have ANY QUESTIONS.
BRYAN

Jim Dailey



Jim Dailey



NAMI/ ASTRAZENECA MEETING

AstraZeneca Headquarters Wilmington, Delaware

December 16, 2003

ATTENDEES

National Alliance Mental Illness Attendees:

Mike Fitzpatrick, Director Policy Research Institute

Jim Dailey, Treasurer Board of Directors

Chuck Harmon, Director of Corporate Relations

AstraZeneca Attendees:

Michael Hickey, Vice President Sales

Marianne Jackson, National Sales Director, CNS P&I

Brian Smith, Area Sales Director, CNS P&I

Chuck Peipher, Brand leader, Managed Markets

Heather Law, Public Affairs Associate

Jeff Mollison, Regional Sales Director, CNS P&I

Bev Susman, Specialty Care Sales

Bryan Clemons, Specialty Care Sales

NAMI/ ASTRAZENECA MEETING

AstraZeneca Headquarters Wilmington, Delaware

December 16, 2003

AGENDA

10:15 – 10:45 AM	Arrivals	Main Lobby
11:00 – 11:45 AM	Guest Tour of USBC	USBC
12:00	Lunch	B2B-621
	Welcome, Introductions, and Overview of Objectives	B2B-621
	Seroquel Vision <ul style="list-style-type: none">• Role of Advocacy Groups• Increasing role of State/Medicaid with MH issues and MAP initiatives• Ensuring access for patients	Michael Hickey or Marianne Jackson
	NAMI Presentation <ul style="list-style-type: none">• NAMI Overview and Strategy, Partnering opportunities, Mind of America Program• MH Access & future issues/concerns: Single State example• Current activities within industry	Mike Fitzpatrick Jim Dailey Chuck Harmon
2:30 – 3:00 PM	Moderated Discussion	All
3:00 PM	Adjourn	



CONFIRMATION FAX

Date: November 19, 2003
To: Jim Dailey
From: Leave It To LaFever, Ltd.
Reference: AstraZeneca
Number of Pages: (Including Cover Page): 1
Comments:

We have received your registration form for the AstraZeneca 2003 Seroquel Consultant Meeting, December 16, 2003 at the AstraZeneca US Business Center in Wilmington, Delaware. You are **confirmed** for this program. If you have any questions please call us at 412-262-7960.

If you are flying please contact:

Sandy Berardis at Centre for Travel
Toll Free: 1-800-255-2140 Ext. 121

(Identify yourself as AstraZeneca December 16th Program.)

You will be receiving a confirmation packet in the mail a few weeks prior to the event.

Please notify Leave It To LaFever, Ltd of any changes. Thank you.

Toll Free Number: 1-866-523-3837

Telephone Number: 412-262-7960

Fax Number: 412-262-7895

LEAVE IT TO LAFEVER, LTD.